Abstract:Lung cancer is a leading cause of cancer-related deaths, contributing to 18.4% of cancer deaths globally. Treatment of non-small cell lung carcinoma has seen rapid progression with targeted therapies tailored to specific genetic drivers. However, identifying genetic alterations can be difficult due to lack of tissue, inaccessible tumors and the risk of complications for the patient with serial tissue sampling. The liquid biopsy provides a minimally invasive method which can obtain circulating biomarkers shed from the tumor and could be a safer alternative to tissue biopsy. While tissue biopsy remains the gold standard, liquid biopsies could be very beneficial where serial sampling is required, such as monitoring disease progression or development of resistance mutations to current targeted therapies. Liquid biopsies also have a potential role in identifying patients at risk of relapse post treatment and as a component of future lung cancer screening protocols. Rapid developments have led to multiple platforms for isolating circulating tumor cells (CTCs) and detecting circulating tumor DNA (ctDNA); however, standardization is lacking, especially in lung carcinoma. Additionally, clonal hematopoiesis of uncertain clinical significance must be taken into consideration in genetic sequencing, as it introduces the potential for false positives. Various biomarkers have been investigated in liquid biopsies; however, in this review, we will concentrate on the current use of ctDNA and CTCs, focusing on the clinical relevance, current and possible future applications and limitations of each.

[Advances in Liquid Biopsy and Its Clinical Application in the Diagnosis and Treatment of Non-small Cell Lung Cancer].

Blood-based Tumor Markers in Lung Cancer

Liquid biopsies for cancer: From bench to clinic

Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer

Liquid biopsy in cancer current: status, challenges and future prospects

Liquid Biopsy in the Clinical Management of Cancers

Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer

Update on liquid biopsy in clinical management of non-small cell lung cancer

Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Liquid biopsy for human cancer: cancer screening, monitoring, and treatment

The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments

Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA

Progress and Application of Circulating Tumor Cells in Non-Small Cell Lung Cancer

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)

Application of Circulating Tumor DNA As a Biomarker for Non-Small Cell Lung Cancer

The advances of the liquid biopsy in colorectal cancer